NCT00084409View on ClinicalTrials.gov

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Lung CancerPrecancerous Condition
Interventions
DRUG

iloprost

Given orally

OTHER

placebo

Given orally

Trial Locations (6)

15232

UPMC Cancer Centers, Pittsburgh

55905

Mayo Clinic Cancer Center, Rochester

80045

University of Colorado Cancer Center at UC Health Sciences Center, Aurora

80220

Veterans Affairs Medical Center - Denver, Denver

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Colorado, Denver

OTHER

NCT00084409 - Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease | Biotech Hunter | Biotech Hunter